MedElevator
Войти в исследования Cisplatin-associated anaemia treated with subcutaneous erythropoietin. A pilot study.
Аннотация
In 20 patients with cisplatin-associated anaemia (haemoglobin less than 90 gl-1), recombinant human erythropoietin was administered subcutaneously three times a week on an outpatient basis. The initial dose was 50 Units Kg-1 of body weight. If response was not achieved within 3 weeks, dose was increased to 75 Units Kg-1. Using the same criteria further escalation to 100 Units Kg-1 was performed. If there was no response erythropoietin was terminated. Fifteen patients obtained an increase in haemoglobin to above 100 gl-1 which was considered as a clinical response in this study, with a dose of 50 Units Kg-1; one patient needed an erythropoietin dose of 75 Units Kg-1 and one a dose of 100 Units Kg-1. Only three patients required haemotransfusions and were considered non responders. Haemoglobin increases occurred despite continuation of cisplatin chemotherapy. In conclusion subcutaneous low dose of erythropoietin seems to be effective and safe in the treatment of cisplatin-induced anaemia.
Перевод полного текста: Перевод в очереди
Полный текст источника
https://creativecommons.org/licenses/by/4.0/ This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/ .
Alexopoulos C. G. Chalevelakis G. Katsoulis C. Pallikaris G. Adverse effect of cis-diamminedichloroplatinum II (CDDP) on porphyrin metabolism in man. 17 2 1986 165 170 Cancer Chemother Pharmacol 3719897 10.1007/BF00306748
Cazzola M. Ponchio L. Beguin Y. Rosti V. Bergamaschi G. Liberato N. L. Fregoni V. Nalli G. Barosi G. Ascari E. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial. 79 1 1 1 1992 29 37 Blood 1728318
Erslev A. J. Erythropoietin. 324 19 9 5 1991 1339 1344 N Engl J Med 2017231 10.1056/NEJM199105093241907
Eschbach J. W. Kelly M. R. Haley N. R. Abels R. I. Adamson J. W. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. 321 3 20 7 1989 158 163 N Engl J Med 2747747 10.1056/NEJM198907203210305
Ludwig H. Fritz E. Kotzmann H. Höcker P. Gisslinger H. Barnas U. Erythropoietin treatment of anemia associated with multiple myeloma. 322 24 14 6 1990 1693 1699 N Engl J Med 2342535 10.1056/NEJM199006143222402
Matsumoto T. Endoh K. Kamisango K. Akamatsu K. Koizumi K. Higuchi M. Imai N. Mitsui H. Kawaguchi T. Effect of recombinant human erythropoietin on anticancer drug-induced anaemia. 75 4 8 1990 463 468 Br J Haematol 2206997 10.1111/j.1365-2141.1990.tb07783.x
McMahon F. G. Vargas R. Ryan M. Jain A. K. Abels R. I. Perry B. Smith I. L. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. 76 9 1 11 1990 1718 1722 Blood 2224121
Miller C. B. Jones R. J. Piantadosi S. Abeloff M. D. Spivak J. L. Decreased erythropoietin response in patients with the anemia of cancer. 322 24 14 6 1990 1689 1692 N Engl J Med 2342534 10.1056/NEJM199006143222401
Miller C. B. Platanias L. C. Mills S. R. Zahurak M. L. Ratain M. J. Ettinger D. S. Jones R. J. Phase I-II trial of erythropoietin in the treatment of cisplatin-associated anemia. 84 2 15 1 1992 98 103 J Natl Cancer Inst 1735886 10.1093/jnci/84.2.98
Oster W. Herrmann F. Gamm H. Zeile G. Lindemann A. Müller G. Brune T. Kraemer H. P. Mertelsmann R. Erythropoietin for the treatment of anemia of malignancy associated with neoplastic bone marrow infiltration. 8 6 6 1990 956 962 J Clin Oncol 2189957 10.1200/JCO.1990.8.6.956
Platanias L. C. Miller C. B. Mick R. Hart R. D. Ozer H. McEvilly J. M. Jones R. J. Ratain M. J. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. 9 11 11 1991 2021 2026 J Clin Oncol 1941061 10.1200/JCO.1991.9.11.2021
Rossof A. H. Slayton R. E. Perlia C. P. Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP). 30 6 12 1972 1451 1456 Cancer 4641756 10.1002/1097-0142(197212)30:6<1451::aid-cncr2820300606>3.0.co;2-q
Rothmann S. A. Paul P. Weick J. K. McIntyre W. R. Fantelli F. Effect of cis-diamminedichloroplatinum on erythropoietin production and hematopoietic progenitor cells. 3 6 11 1985 415 423 Int J Cell Cloning 4067362 10.1002/stem.5530030607
Von Hoff D. D. Schilsky R. Reichert C. M. Reddick R. L. Rozencweig M. Young R. C. Muggia F. M. Toxic effects of cis-dichlorodiammineplatinum(II) in man. 63 9-10 Sep-Oct 1979 1527 1531 Cancer Treat Rep 387223
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.